Лейкоз / лимфома Беркитта: клинические особенности, диагностические критерии, терапевтическая тактика Е. А. Барях, С. К. Кравченко, А. М. Кременецкая, Е. Е. Звонков, А. У. Магомедова, Т. Н. Обухова, Ю. Ю. Попова, О. С. Финк, Г. А. Клясова, Е. М. Шулутко, Г. М. Галстян, И. Б. Капланская, И. А. Воробьев, А. И. Воробьев

Elena Alexandrovna Baryakh, С К Кравченко, Aleksandra Mikhaylovna Kremenetskaya et al. · CyberLeninK (CyberLeninka) · 2010

SUMMARY Burkitt lymphoma (BL) is the most aggressive B-cell lymphoid neoplasm, which growth phase fraction approximates 100 %. BL has specific chromosomal abnormalities: (8;14)(q24;q32), rare — t(2;8)(p12;q32)or t(8;22)(q24;q11). Burkitt leukemia / BL is one of the stages of Burkitt lymphoma according to S. B. Murphy’s classification (blasts > 25 %). 23 patients with BL (with c-myc rearrangement), 15 males and 8 females, mean age 24 years (15–51) were eligible for our study performed in the Russian Hematological Research Center between 1995 and 2009. The main diagnosis criteria of BL are: translocation t(8;14)(q24;q32) or variant c-myc rearrangement, blasts in bone marrow > 25 %, young age, rapid tumor progression, bulky disease, tumor localization in abdominal and / or retro abdominal cavity, B-symptoms, increased LDG level, high number of Ki-67-positive cells approximates 100 %; CD10+, bcl-6+; sIgM+. 16 patients were included in high intensive short term protocol BL-M-04 (2003–2009). The 5-year disease-free survival was 87 % with an overall survival of 81 %. Most infectious and hemorrhagic complications occurred during the first course (course A), which can be explained by the initial poor condition of the patients. The use of this protocol can achieve rapid tumor regression with short treatment duration due to the chemotherapy intensification.

Cited by 0 works.

Authors

References